BioMedNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Enters SAA with Samsung

HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D vector electrocardiogram (“VECG”) platform intended for patient use at home, today announced its entry into a strategic alliance agreement (“SAA”) with Samsung, extending the existing SAA between LIVMOR and Samsung. HeartBeam acquired LIVMOR assets earlier this year. Under the agreement, HeartBeam and Samsung will identify and define opportunities for collaboration, tapping the HeartBeam team’s expertise and patented technology in the assessment and monitoring of cardiac symptoms. “The goal of this partnership is to bring standard of care for cardiac diagnostic capabilities to patients by utilizing cutting-edge technologies of both Samsung and HeartBeam,” said Branislav Vajdic, Ph.D., HeartBeam CEO and founder. “Our newly acquired state-of-the-art, FDA cleared, Samsung watch-based arrhythmia detection tool, once integrated with the HeartBeam AIMIGo(TM) telehealth platform, presents a unique opportunity to extend our product capabilities well beyond what is currently available for cardiac patients outside of a medical setting.”

To view the full press release, visit https://ibn.fm/zLoVO

About HeartBeam Inc.

HeartBeam is a cardiac technology company that has developed the first and only 3D-vector ECG platform intended for patient use at home. By applying a suite of proprietary algorithms to simplify vector electrocardiography (“VECG”), the HeartBeam platform enables patients and their clinicians to assess their cardiac symptoms quickly and easily, so care can be expedited, if required. HeartBeam has two patented products in development. HeartBeam AIMI(TM) is software for acute care settings that provides a 3D comparison of baseline and symptomatic 12-lead ECG to more accurately identify a heart attack. HeartBeam AIMIGo(TM) is the first and only credit card-sized 12-lead output ECG device coupled with a smart phone app and cloud-based diagnostic software system to facilitate remote evaluation of cardiac symptoms. HeartBeam AIMI and AIMIGo have not yet been cleared by the U.S. Food and Drug Administration (“FDA”) for marketing in the USA or other geographies. For more information, visit www.HeartBeam.com.

NOTE TO INVESTORS: The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork